Opendata, web and dolomites

TRIBBLES SIGNED

Characterizing the clinical relevance and the mechanism underlying TRIB2-mediated drug resistance to MEK inhibitiors in the context of melanoma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "TRIBBLES" data sheet

The following table provides information about the project.

Coordinator
UNIVERSIDADE DO ALGARVE 

Organization address
address: CAMPUS DE PENHA
city: FARO
postcode: 8005 139
website: www.ualg.pt

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Total cost 160˙635 €
 EC max contribution 160˙635 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2020-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSIDADE DO ALGARVE PT (FARO) coordinator 160˙635.00

Map

 Project objective

Melanoma is the most aggressive form of skin cancer resistant to all standard therapies. Currently, the established treatment of metastatic melanoma includes dacarbazine (DTIC) administration associated with response rates of between 10-20% with severe side effects during treatment. Recently, the BRAF inhibitors (vemurafenib and dabrafenib) and the MEK inhibitor (trametinib) were approved for the treatment of melanoma patients with mutated BRAF (about 50% of patients) while there are several PI3K, AKT, mTOR and MEK inhibitors being tested in clinical trials. However, the effectiveness of all these treatment modalities is limited by intrinsic or acquired resistance. The host lab has discovered a novel mechanism of resistance to a broad spectrum of drugs in clinical trials/use for melanoma therapy mediated by the kinase-like protein TRIB2. This means that TRIB2 could be used as a biomarker to select melanoma patients for specific treatment options and to develop co-treatment strategies to overcome drug resistance. This project pretends to (1) understand the mechanisms underlying TRIB2-mediated resistance to MEK inhibitors and to (2) further develop TRIB2 as a prognostic and predictive biomarker for melanoma. Ultimately, the expected results will be highly relevant for the clinic as they might allow to select melanoma patients for specific treatment options and to develop co-treatment strategies to overcome TRIB2 mediate resistance.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRIBBLES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRIBBLES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

Goc-MM (2019)

Human gut microbiota on gut-on-a-chip

Read More  

POSPORI (2019)

Polymer Optical Sensors for Prolonged Overseeing the Robustness of civil Infrastructures

Read More  

ACES (2019)

Antarctic Cyclones: Expression in Sea Ice

Read More